Getinge Earnings Call: Strong Core, Heavy Tariff Drag

Getinge AB ((GNGBY)) has held its Q4 earnings call. Read on for the main highlights of the call.

Getinge Balances Solid Operations With Heavy Tariff Headwinds in Latest Earnings Call

Getinge’s latest earnings call painted a cautiously constructive picture: operationally the company is performing well, with record sales, improving underlying margins, strong cash generation and an increasingly attractive recurring revenue mix. Yet this strength is being masked in reported numbers by significant external headwinds from tariffs and foreign exchange, alongside pockets of weakness in Life Science and product‑specific supply constraints. Management stressed confidence in its strategy and cost actions, but acknowledged that these factors will weigh on profitability into 2026, leaving investors with a balanced risk‑reward profile.

Record Quarter for Sales and Orders

Getinge delivered a new record quarter for revenue, with organic net sales up 1.2% year‑on‑year, despite a tough comparison with last year’s all‑time high. Order intake grew organically by 2.3%, signaling continued demand across key franchises. While the growth rate is modest, it comes on top of a strong base and underscores the resilience of the company’s core hospital and life science customer base in a still‑uncertain macro environment.

Underlying Margins Track Toward 2028 Target

Beneath the surface of FX and tariff volatility, profitability is moving in the right direction. Adjusted EBITA margins, excluding currency and tariff effects, would have reached 20.3% in the quarter and 16.0% for the full year. This puts Getinge firmly on the trajectory toward its 16–19% adjusted EBITA margin target for 2028. The improvement reflects mix benefits, operating leverage and ongoing productivity measures, suggesting that the core business model is structurally stronger than the headline numbers imply.

Solid Profitability and Robust Cash Generation

Despite external pressures, Getinge posted solid earnings and cash flow. Adjusted gross profit came in at SEK 5.037 billion in the quarter, with adjusted EBITDA of SEK 1.809 billion, corresponding to a 17.8% margin. Free cash flow of SEK 1.2 billion underlines the company’s ability to convert earnings into cash, an important comfort factor for investors at a time when reported margins are under pressure. The combination of healthy profitability and strong cash generation provides flexibility to navigate ongoing headwinds.

Strengthened Balance Sheet and Shareholder Returns

The balance sheet remains a clear bright spot. Net debt stood at SEK 9.8 billion, or SEK 7.5 billion excluding pensions, with leverage at 1.5x adjusted EBITDA (1.1x on a pension‑adjusted basis), giving the company ample financial headroom. Cash on hand is about SEK 3.4 billion, supporting both operational resilience and capital allocation optionality. Reflecting confidence in its financial position, the Board proposed a dividend of SEK 4.75 per share, signaling a continued commitment to shareholder returns alongside investment in growth and quality initiatives.

Higher Share of Recurring and High‑Margin Revenue

Getinge is steadily reshaping its revenue profile toward more stable and profitable streams. Recurring revenue now accounts for roughly two‑thirds of total sales, increasing earnings visibility and reducing cyclicality. Within that mix, the share of higher‑margin products and consumables—such as Paragonix devices, the ECLS portfolio, infection control consumables and Cell Transfer data bags—has risen. This shift supports margin expansion over time and makes the portfolio less dependent on lumpy capital‑equipment cycles.

Accelerated Product Launches and Regulatory Wins

Innovation and regulatory progress were prominent themes in the quarter. Getinge rolled out several new products, including the Siemens user interface for washers and sterilizers, the Aquadis 44 washer and the Automatiq platform, aiming to sharpen competitiveness in Surgical Workflows and infection control. On the regulatory front, the company secured CE marking for the PLS set under the EU MDR, gained approval for larger diameters of its iCast covered stent, and saw its PiCCO technology included in a European guideline—each enhancing the commercial potential of these lines. Importantly, the CE submission for Cardiohelp II was completed, with first European shipments expected early in the year, marking a key milestone in the Acute Care Therapies portfolio.

Commercial Momentum in Core Hospital Markets

Operationally, many of Getinge’s core businesses are performing well. Acute Care Therapies showed good momentum, supported by ventilators, Transplant Care and ECLS consumables, where clinical demand remains strong. Surgical Workflows also posted healthy development, driven by operating tables and infection‑control consumables, both of which benefit from ongoing investments in hospital efficiency and hygiene. In Life Science, sterile transfer remained a bright spot, demonstrating resilience even as some sub‑segments softened.

Tariffs and FX Severely Pressure Reported Results

The biggest drag on headline performance came from external factors. Tariffs and currency combined were a material hit to profitability, with more than SEK 1 billion of negative impact on adjusted EBITDA for the year. Tariff costs alone were around SEK 370 million in 2025, including roughly SEK 150 million just in the fourth quarter, while FX and tariffs together shaved nearly SEK 500 million off Q4 results. These forces are largely outside management’s control and significantly obscure the underlying margin progress seen on an operational basis.

Reported Margins Compress Despite Operational Progress

The external pressures showed up clearly in reported margins. Adjusted gross margin fell by 1.1 percentage points in the quarter, and FX alone reduced the EBITA margin by about 1.2 percentage points. The adjusted EBITDA margin of 17.8% was down versus prior periods primarily because of FX and tariffs, not because of weaker operations. For investors, this creates a disconnect between what the business is earning on a like‑for‑like basis and what is visible in the reported figures, reinforcing the importance of adjusting for these factors when assessing profitability trends.

Life Science Segment Faces Softer Demand

While the hospital‑focused businesses held up well, parts of Life Science turned weaker in the quarter. Both order intake and organic net sales declined, reflecting softness in washing, isolators and sterilizers (WIS), as well as in Bio‑Processing. Exposure to slower bioprocessing markets, including China, weighed on performance as customers delayed projects and spending. This segment remains strategically important, but its near‑term outlook is clouded by macro and sector‑specific headwinds, making it a watch point for 2026.

Supply Constraints and Delays Hit CardioSave and IABP

Supply chain disruptions and regulatory constraints continue to affect some critical products. CardioSave shipments were delayed after CE marking was reinstated with conditions, pushing deliveries into the second quarter of 2026. The 510(k) submission for CardioSave was also postponed to Q2 2026 due to shortages of key components. Intra‑aortic balloon pump (IABP) supply restrictions limited U.S. sales largely to replacement pumps, constraining growth in this high‑acuity segment. These issues create temporary revenue gaps and underscore the execution risk associated with complex medical device supply chains.

Surgical Perfusion Phase‑Out Creates 2026 Revenue Headwind

Another drag on future top‑line growth will come from the planned phase‑out of the Surgical Perfusion business. Net sales from this category are expected to fall sharply from about SEK 250 million to approximately SEK 50 million in 2026. While this step is incorporated into the company’s guidance and reflects portfolio pruning rather than underlying demand weakness, it nonetheless represents a meaningful headwind to reported growth in the coming year.

Elevated Quality and Remediation Costs to Ease Gradually

Quality remediation and related extraordinary costs remained elevated over the past year and are expected to stay high in 2025, although management reaffirmed that they will be kept below SEK 800 million. These costs, which sit on top of normal operating expenses, weigh on near‑term margins but are aimed at strengthening the company’s quality systems and regulatory robustness. Getinge expects a turning point from the second half of 2026, with a material reduction in these extraordinary costs in 2027 and 2028—another lever for medium‑term margin expansion once the heavy lifting is done.

Geopolitics, China and Macro Uncertainty Remain a Drag

Management highlighted ongoing geopolitical and macroeconomic uncertainties as a structural risk to the outlook. Tariff and FX volatility are expected to persist into 2026, with tariffs alone potentially representing a roughly SEK 0.5 billion headwind. At the same time, the company is seeing delayed customer project decisions and intensified competition in China, particularly in more commoditized segments. These factors add to forecasting complexity and underline the need for continued pricing discipline and cost control.

Guidance: Modest Growth Target with Margin Ambitions Intact

Looking ahead, Getinge guided to organic net sales growth of 3–5% for 2026, adjusting for the Surgical Perfusion phase‑out from roughly SEK 250 million to about SEK 50 million in sales. The company reiterated its mid‑term ambition for an adjusted EBITA margin of 16–19% by the end of 2028, effectively reaffirming confidence in the underlying earnings power despite external headwinds. Management expects tariffs and FX to remain a drag—tariffs cost around SEK 370 million in 2025 and about SEK 150 million in Q4 alone, with at least SEK 0.5 billion anticipated in 2026—but plans to counter this via approximately 2% price increases, ongoing productivity actions and the commercial ramp‑up of new and upgraded products such as Cardiohelp II and, later, CardioSave once regulatory milestones are met. A strong financial position, including Q4 adjusted EBITDA of SEK 1.809 billion (17.8% margin), free cash flow of SEK 1.2 billion, net debt of SEK 9.8 billion (SEK 7.5 billion excluding pensions) and cash of about SEK 3.4 billion, underpins this plan, alongside the proposed dividend of SEK 4.75 per share.

In sum, Getinge’s earnings call showcased a company with strengthening operational fundamentals but facing an unusually heavy overlay of external and transitional headwinds. Record sales, improving underlying margins, a rising share of recurring and high‑margin revenue, and a solid balance sheet all support a constructive medium‑term story. At the same time, tariffs, FX, Life Science softness, product‑specific delays and elevated quality costs will continue to cloud reported results in the near term. For investors, the key question is whether Getinge can deliver on its cost and pricing initiatives quickly enough to unlock the margin potential that its underlying performance suggests.